NCT03510104 2026-01-08
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Meryx, Inc.
Phase 1 Completed
Meryx, Inc.
Corcept Therapeutics
AVEO Pharmaceuticals, Inc.
Tracon Pharmaceuticals Inc.